Go Makimoto

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

Hiromi Watanabe, Eiki Ichihara, Hiroe Kayatani et al. · Cancer Science · 2021 · 47 citations · Full text

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

Kiichiro Ninomiya, Kadoaki Ohashi, Go Makimoto et al. · Scientific Reports · 2018 · 45 citations · Full text

Immunology, Pharmacotherapy, Cancer Biology +19

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)

Kiichiro Ninomiya, Tae Hata, Hiroshige Yoshioka et al. · CHEST Journal · 2019 · 36 citations

Cancer Epidemiology, Medicine, Epidemiology Of Cancer +9

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

Satoru Senoo, Takashi Ninomiya, Go Makimoto et al. · Internal Medicine · 2018 · 31 citations · Full text

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring <i><scp>ROS</scp>1</i> fusions

Yuka Kato, Kiichiro Ninomiya, Kadoaki Ohashi et al. · Cancer Science · 2018 · 29 citations · Full text